Bleeding Disorders
News
Low inhibitor rate observed in PUPs with hemophilia A
Researchers have observed a low inhibitor rate in previously untreated patients (PUPs) with severe hemophilia A who received treatment with...
News
EC approves product to treat hemophilia A
The European Commission (EC) has granted marketing authorization for rurioctocog alfa pegol (Adynovi). Rurioctocog alfa pegol (formerly BAX 855)...
News
Emicizumab still available despite legal issues
The Roche Group has issued a statement reassuring the US hemophilia community that legal issues are not affecting patient access to emicizumab (...
Conference Coverage
Update of gene therapy in hemophilia A
ATLANTA—Updated trial results have shown that gene therapy can increase factor VIII (FVIII) levels and reduce the need for FVIII infusions in...
Conference Coverage
Caplacizumab improves outcomes in aTTP
ATLANTA—Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at...
News
FDA grants breakthrough therapy designation for severe aplastic anemia drug
Eltrombopag, from Novartis, will get expedited review for first-line treatment of severe aplastic anemia. It is already approved as a second-line...
Conference Coverage
Study identifies predictors of acquired von Willebrand disease
ATLANTA – Successfully treating Waldenström macroglobulinemia often resolves acquired von Willebrand disease.
News
FDA okays dosing software for hemophilia A
The newly cleared software is designed for use in developing personalized prophylaxis regimens for patients with hemophilia A.
News
FDA okays dosing software for hemophilia A
The newly-cleared software is designed for use in developing personalized prophylaxis regimens for patients with hemophilia A.
News
FDA lifts clinical hold on fitusiran trials
The US Food and Drug Administration (FDA) has lifted the hold on clinical trials of fitusiran, an RNAi therapeutic being developed to treat...
Conference Coverage
VIDEO: Caplacizumab sped platelet response, improved clinical outcomes in acquired TTP
ATLANTA – Phase 2 data on aTTP earned caplacizumab an FDA fast track designation in July 2017.